PHARMASEAL International, provider of clinical trials management systems has announced that it will offer the Engility® CTMS solution at no cost for COVID-19 Coronavirus clinical trials. The free offer to utilize Engility CTMS is open to biopharmaceutical organizations and academic institutions.
How Engility CTMS will help?
Engility CTMS is cloud-based, with rapid implementation and can be used to manage the full lifecycle of clinical trials including associated regulatory documentation.
Innovative companies that are at the forefront of discovering new medicines to combat the Coronavirus need to be supported with agile technologies and working practices. Engility CTMS allows them to centralize their clinical trial information providing control and unified governance of their COVID-19 trials and associated partners and collaborators. The change to a distributed workforce and remote working enforced by the current pandemic means the use of remote and centralized monitoring is accentuated and readily supported by Engility CTMS.
Daljit Cheema, CEO said ‘The PHARMASEAL team is committed to supporting global life science businesses to improve patients’ lives and would like to further extend this commitment and support during this pandemic to bring treatments to market faster.’
Engility CTMS is a SaaS cloud platform built with agility at its core and intelligently engineered to evolve. The progressive platform is designed to rapidly deliver new product updates within a continuous validation framework facilitating accelerated innovation. It is flexible and scalable in order to meet the needs of all organizations.
For further information on PHARMASEAL, please contact us via email [email protected]
For all press enquires please contact Sally Vernon via email [email protected]
This article was written by Medilink EM Member, PHARMASEAL.
